The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

Eleven forms of cancer are becoming increasingly common among young people in England. Experts at the Institute of Cancer Research and Imperial College London stressed that cancer among younger people is still rare, and that everyone can reduce their risk by simply switching to a healthier lifestyle. However, why tumours have started to develop in people in their late teens, or in their 20s, 30s and 40s, remains unclear. The study further shows that the reasons behind rising cancer cases are elusive. However, this research does indicate a decade-long pattern of people becoming overweight.

Why does one develop cancer?

A team of scientists worked towards understanding why a person develops cancer. They examined national trends in lifestyle and cancer to identify patterns. Researchers found that cases of the following types of cancer were rising:

1. Liver
2. Kidney
3. Thyroid
4. Bowel
5. Multiple myeloma
6. Womb lining
7. Mouth
8. Ovarian
9. Breast
10. Gallbladder
11. Pancreatic

Researchers found that breast and bowel cancers are common among younger adults, with 11,500 cases in a year, while gallbladder and pancreatic cancers were much rarer. It was also noted that ovarian and bowel cancers were exclusively being reported in young people, whereas the other nine were increasing in adults as well. The study by the Institute of Cancer Research and Imperial College London also analysed behavioural patterns known to raise cancer risk.

Researchers also found patterns related to alcohol intake, smoking levels, red and processed meat consumption, and diets low in fibre. These factors play a role in cancer development, but do not conclusively explain why cancer rates are increasing. Century-old tumour patterns, however, may explain why younger people are getting bowel cancer.

How to check for bowel cancer risk?

The report suggested that the only factors that align with an increased risk of cancer are obesity and being overweight, both of which have been on the rise since the 1990s. Extra fat tissue can alter hormones such as insulin, which can increase cancer risk. For instance, in the case of bowel cancer, for every 100 extra cases, 20 could be attributed to excess weight, while 80 remain unexplained. Researchers also note that it is important to prevent all cancers, not just the additional cases. It is estimated that nearly 40 per cent of cancers worldwide can be prevented through appropriate lifestyle choices, such as quitting smoking.

How to reduce cancer risk?

Quitting smoking and avoiding alcohol are among the simplest and most well-known ways of reducing cancer risk. However, experts say that other measures can also help. Maintaining a healthy body weight and staying physically active are simple ways to reduce cancer risk. Researchers also emphasise that while cancer rates are rising among younger people, the risk of tumours remains significantly higher in older age groups.

Researchers found that one in 1,000 people aged 20, 30 and 40 are diagnosed with cancer every year, compared to one in 100 among older age groups aged 50, 60 and 70. The search for other risk factors continues. Inflammation, sweetened drinks, gut bacteria, and air pollution must be addressed in time to reduce cancer risk. It is also being investigated whether improvements in cancer detection are contributing to earlier diagnoses in younger individuals.

The study’s findings are published in the BMJ Oncology.

After a long day at work, the occasional glass of wine helps many people unwind. However, some struggle to strike a balance and get involved in binge drinking habits. If you are someone who is unable to give up that frequent dose of cocktails, then a study claims that weight loss drugs can come to your rescue. Experts have found that alcoholics who are obese, when given Wegovy, could curb their drinking habits by as much as 70 per cent. A study in Denmark was led by experts from the Mental Health Centre Copenhagen and Frederiksberg Hospital, and experts used semaglutide on 108 obese patients seeking treatment for alcohol use disorder.

Can weight loss drugs help curb drinking habits?

Half the participants in the study were given 2.4 mg of the drug for six months. The other half were also given a dummy drug. Researchers found that people who were on weight loss drugs had fewer days of binge drinking. Furthermore, their alcohol cravings also dipped compared to people on placebo. Before the trial began, participants engaged in binge drinking on an average of 17 days per month.

Researchers also noted that people who were given semaglutide for six months saw their binge drinking days reduce to five in a 30-day period. This correlated to a 40 per cent dip in drinking days in a month, compared to a 26 per cent dip in the placebo group. These dummy drugs helped reduce drinking days to nine. In terms of alcohol quantity, trial participants drank roughly 2,200 g in the 30 days before the trial started. This meant about 154 drinks in a month, or five per day. Over a period of six months after the trial, there was an impressive 70 per cent dip — from an average of 154 drinks a month to 46 drinks a month in people who were taking semaglutide.

What are the benefits of semaglutide?

Alcohol consumption dipped by an impressive 47 per cent in the dummy drug group as well. The study found that overall alcohol consumption can be reduced among semaglutide users compared to people who were taking the placebo. Researchers found that semaglutide not only affects appetite but also influences biological mechanisms associated with addiction.

Independent researchers found that the results were encouraging and strong enough to be used in helping people struggling with alcohol use problems. However, more research is required in this area. Researchers also noted that there were no follow-ups with the participants after the semaglutide treatment ended. This means that experts could not be fully certain whether people reverted to their old drinking habits once they stopped using the medicine.

What are the health benefits of weight loss drugs?

Apart from inducing weight loss, weight loss drugs have the following health benefits:

1. Quitting smoking
2. Can help kick drug habits such as cocaine use
3. Lower risk of heart attack or stroke
4. May help reduce blood pressure and cholesterol to improve heart health
5. Lower risk of dementia

A whopping $600 million global vaccine aid meant for poorer nations has been put on hold by US Health Secretary Robert F. Kennedy Jr., according to a media report.

The delay in vaccines is putting pressure on the international humanitarian group Gavi, the Vaccine Alliance that distributes them, Politico reported.

Gavi noted that it has not received the funds due for the current and previous fiscal years, which account for about 15 percent of its budget.

The funds are set to expire on September 30 if the Trump administration does not release them.

The organization provides vaccines for 20 diseases, including measles, malaria and polio, to more than 50 low-income countries worldwide.

Sania Nishtar, Gavi CEO, told the newswire AFP, the funding gap, combined with reductions from other donors, has particularly impacted malaria vaccination efforts.

Gavi has delivered 39 million doses of a malaria vaccine to 25 African countries, where the disease predominantly affects children under five. Nishtar warned that tens of thousands of children could die as a result of the funding cuts.

Why Is Kennedy Holding Up Vaccines

Kennedy argues that the shots are obsolete with dangerous ingredients that the US has long since phased out.

“Gavi has refused to provide the United States with the specific data, studies, or detailed accounting of how US funds are used,” Emily Hilliard, senior press secretary at the Health and Human Services Department, said in a statement.

Advocates for Gavi, the Vaccine Alliance warn that withholding funds could cost children’s lives. They argue that the vaccines used are safe and better suited for developing regions, where refrigeration is limited and administering booster doses is more difficult.

Hilliard said Gavi has declined to create a plan to phase out thimerosal, a mercury-based vaccine preservative that Kennedy believes may be linked to autism. The administration has asked Gavi to stop using vaccines containing this preservative.

Thimerosal is used in several vaccines distributed by Gavi, including combination shots protecting against multiple diseases, according to former chief executive Seth Berkley. He explained that many developing countries rely on multi-dose vials, which require less refrigeration but may contain thimerosal to prevent contamination.

Without such vaccines, “kids would go without vaccines… and that would lead directly to deaths,” Berkley said.

During testimony before the Senate Appropriations Committee, Kennedy also raised concerns about a vaccine used to protect against diphtheria, tetanus and pertussis, claiming it had been discontinued in the US due to safety issues.

Gavi responded that the vaccine remains in use because it offers longer-lasting protection and requires fewer doses. The organization said the vaccine “is safe and effective and estimated to have saved 40 million lives in the past 50 years,” the report said.